With respect to our formulations, which are proprietary, we have patented our KH-30 oil well cleaner in the United States, Australia, Russia, Nigeria, Venezuela, Vietnam and OAPI. We also have 12 additional country patent applications pending in most of the major oil-producing countries around the world (including the European Union and Canada). We believe our patent is strong and will help our competitive position. However, we are aware that others may try to imitate our product or invalidate our patents. We have in the past vigorously enforced our trade secrets such as the one relating to our Uniproof proofing paper, and intend to continue to do so in the future. However, we recognize that intellectual property rights provide less than complete protection. We believe that no other company is currently producing a product similar to KH-30.
In addition to applying for patent protection on our KH-30 product, we have also registered “KH-30” as a trademark. Trademark protection has also been obtained for the “Uniproof” name for our proofing paper. We anticipate applying for both patent and trademark protection for our other products in those jurisdictions where we deem such protection to be beneficial.
Net Loss. The three months ended December 31, 2004 resulted in a net loss of $(357,498) or $(0.02) per share as compared to a net loss of $(555,963) or $(0.03) per share for the three months ended December 31, 2003. The decrease in the loss in the quarter ended December 31, 2004 was the result of an increased level of Uniproof proofing paper sales during the quarter and an increased level of our specialty chemical sales along with the relatively lower level of general and administrative expenses. The average number of shares of common stock used in calculating earnings per share increased 230,975 shares to 22,411,245 as a result of 162,497 shares issued for the conversion of the note payable and 75,000 shares issued for consulting services.
Nine months Ended December 31, 2004 Compared to the Nine months Ended December 31, 2003
Revenues. Revenues for the nine months ended December 31, 2004 were $1,192,499; a $406,237 or 52% increase from revenues of $786,262 in the comparable nine months ended December 31, 2003. The increase in revenues was due to higher sales of Specialty Chemicals and Uniproof proofing paper. Specialty Chemicals, which include sales of our KH-30 products and Green Globe/Qualchem military sales, increased $342,662 to $643,257, or 114% compared to $300,595 in the comparable nine months ended December 31, 2003. The increase was primarily related to a 171% increase in sales of our KH-30 family of oil field dispersant products reflecting a higher level of orders partially offset by a 32% decline in Green Globe/Qualchem military sales. Uniproof proofing paper sales increased $63,575 due to higher level of orders from our primary customer.
Cost of Goods Sold. Cost of goods sold increased 43% to $564,885 or 47% of sales, for the nine months ended December 31, 2004 from $396,380 or 50% of sales, for the nine months ended December 31, 2003. The increase in cost of goods sold was due to the increased sales of KH-30 products compared to the prior year and an increase in volume of Uniproof proofing paper sales
Gross Profit. Gross profit for the nine months ended December 31, 2004 was 53% or $627,614, a $237,732 or 61% increase from a 50% gross profit or $389,882 in the corresponding period of fiscal 2003. Gross profit increased due to higher levels of our specialty chemical sales with higher gross profit margins along with higher levels of sales of Uniproof proofing paper. Gross profit percentage increased due to higher levels of sales and lower costs associated with specialty chemicals, which was partially offset by higher costs associated with Uniproofing paper sales.
Operating Costs and Expenses
General and Administrative Expenses. General and administrative expenses decreased $87,235, or 4% to $1,938,043, or 163% of revenues for the nine months ended December 31, 2004 from $2,025,278, or 258% of revenues for the nine months ended December 31, 2003. The slight decrease in general and administrative expenses was primarily related to lower salaries and benefits due to the departure of certain executives, lower travel and entertainment expenses and laboratory expenses partially offset by an increase in professional fees and marketing.
Depreciation, Amortization and Depletion. Depreciation, amortization and depletion decreased to $87,046 from $114,403 reflecting additions to fixed assets and capitalized legal costs related to patent filings, offset by the sale of oil leases. Depletion expense was not material.
Oil Well Operating and Maintenance Cost-net. During the nine months ended December 31, 2003, the wells produced oil, which generated $34,636 in revenues and incurred operating costs and maintenance and repair costs of $137,298.
Interest Income, Net of Interest Expense. The Company had net interest expense of $200,577 for the nine months ended December 31, 2004 compared with net interest income of $6,233 in the corresponding period in 2003. The decrease was due to interest on the $1,750,000 convertible term note payable.
Net Loss. The nine months ended December 31, 2004 resulted in a net loss of $(1,598,052) or $(0.07) per share compared to a net loss of $(1,846,228) or $(0.08) per share for the comparable period ended December 31, 2003. The decrease in the loss in the nine months ended December 31, 2004 was the result of an increased level of our specialty chemical sales and a slightly decreased level of total operating expenses. The average number of shares of common stock used in calculating earnings per share increased by 129,058 to 22,309,328 shares at
18
December 31, 2004 compared with 22,180,270 at December 31, 2003 as a result of 162,497 shares issued for the conversion of the note payable and 75,000 shares issued for consulting services.
Liquidity and Capital Resources
As of December 31, 2004, the Company had $73,213 in cash and cash equivalents, as compared to $1,518,025 at March 31, 2004.
The $1,444,812 decrease in cash and cash equivalents was due to net cash used in operating activities of $1,426,285 and net cash used in investing activities of $18,527. Cash used in investing activities consisted of payments of $8,375 related to patent applications for KH-30 and the purchase of production equipment and other fixed assets of $26,053, which was partially offset by payment on loans of $901 and $15,000 of proceeds from the sale the oil well leases.
On March 24, 2004, pursuant to a Security Purchase Agreement dated as of the same date, we completed the sale of a secured convertible term note in the principal amount of $1,750,000. The note, which has a term of three years and accrues interest at the greater of prime rate of interest (as published in the Wall Street Journal) or 4% per annum, is convertible into shares of our common stock at a conversion price of $1.00 per share. During the nine month period ended December 31, 2004, the holder of the note has converted $150,000 in principal into 150,000 shares of common stock. In addition, the holder of the note received $12,497 of interest in shares of common stock. During December 2004, the Company defaulted on the note by failing to pay principal of $24,999. The Company has also failed to pay principal of $116,666 for January and February 2005. The Company has not received written notice of default from the holder of the note. If written notice is received, the Company will be subject to an acceleration clause. In the event of such acceleration, the amount due and owing to the holder shall be 120% of the outstanding principal amount of the note (plus accrued and unpaid interest and fees, if any).
As of December 31, 2004, the Company’s backlog included $580,525 of specialty chemical sales. Backlog represents products that the Company’s customers have committed to purchase. The Company’s backlog is subject to fluctuations and is not necessarily indicative of future sales.
During the past two fiscal years ended March 31, 2004 and 2003, the Company has recorded aggregate losses from operations of $5,398,098 and has incurred total negative cash flow from operations of $4,911,943 for the same two-year period. During the nine months ended December 31, 2004, the Company experienced a net loss from operations of $1,598,052 and negative cash flow from operating activities of $1,426,285. As described above, the Company defaulted on the Secured Convertible Term Note by failing to pay principal of $141,665 during December 2004, January and February 2005. The Company does not currently have an operating line of credit. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
The Company’s continued existence is dependent upon several factors, including increased sales volume, collection of existing receivables, the ability to achieve profitability from the sale of the Company’s product lines and curing the default of the company’s debt. The Company is pursuing an equity investment from an independent investment banking company; however, the Company does not have a firm commitment for such financing, and there can be no assurance that the Company will be able to attain such financing or if so, on economically attractive terms. In order to increase its cash flow, the Company is continuing its efforts to stimulate sales and cut back expenses not directly supporting its sales and marketing efforts.
Concentration of Risk
The Company sells its Uniproof proofing paper to three customers. One of these customers constitutes 99% of Graphic Arts sales and 46% of total customer sales for the nine months period ended December 31, 2004. The loss of this customer would have adverse financial consequences to the Company. We have provided liberal credit terms to this customer and there is a risk that a certain amount of this receivable balance may prove to be uncollectible. The Company believes that this customer will purchase additional product and the Company would use that as leverage to collect any outstanding balances.
19
Quantitative and Qualitative Disclosures about Market Risk
The market risk inherent in our market risk sensitive variable interest rate debt is the potential losses arising from adverse changes in interest rates.
At December 31, 2004, the Company had a loan that had a variable interest rate. The loan, which had an outstanding balance of $1,600,000 at December 31, 2004, was obtained in March 2004 and has a three-year term. The loan accrues interest at the greater of the prime rate of interest (as published in the Wall Street Journal) or 4% per annum. A one-percentage point increase in the prime rate of interest affecting our loan would increase our net loss by $16,000 over a year.
20
| Item 3. | Controls and Procedures. |
Evaluation of the Company’s Disclosure Controls
As of the end of the period covered by this report, the Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures (“disclosure controls”). This evaluation (the “controls evaluation”) was done under the supervision and participation of the Company’s management, including its chief executive officer (the “CEO”) and interim chief financial officer (the “CFO”) pursuant to SEC Rule 13a-15. Rules adopted by the Securities and Exchange Commission require that in this section of the report the Company present the conclusions of its CEO and CFO about the effectiveness of the Company’s disclosure controls based on and as of the date of the controls evaluation.
CEO and CFO Certifications
Appearing as exhibits 31.1 and 31.2 to this report are “Certifications” of the CEO and CFO. The certifications are required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (the “Section 302 Certifications”). This section of this report contains information concerning the controls evaluation referred to in the Section 302 Certifications and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.
Disclosure Controls
Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to the Company’s management, including, without limitation, the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.
Limitations on the Effectiveness of Controls
The Company’s management, including, without limitation, the CEO and CFO, does not expect that the Company’s disclosure controls will prevent all error and fraud. A control system no matter how well conceived and operated can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations of all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.
Scope of Controls Evaluation
The CEO/CFO evaluation of the Company’s disclosure controls included a review of the controls’ objective and design, the controls’ implementation by the Company and the effect of the controls on the information generated for use in this report. In the course of the controls evaluation, management sought to identify data errors, controls problems or acts of fraud and to confirm that appropriate corrective action, including process movements, was being undertaken. This type of evaluation will be done on a quarterly basis so that the conclusions concerning controls effectiveness can be reported in the Company’s quarterly reports on Form 10-QSB and annual report on Form 10-KSB. The overall goals of these various review and evaluation activities are to monitor the Company’s disclosure controls and to make modifications, as necessary. In this regard, the Company’s intent is that the disclosure controls will be maintained as dynamic controls systems that change (including improvements and corrections) as conditions warrant.
21
Conclusions
Based upon the controls evaluation, the Company’s CEO and CFO have concluded that, as of the end of the period covered by this report, the Company’s disclosure controls are effective to provide reasonable assurance that information required to be disclosed in the Company’s reports filed under the Securities Exchange Act such as this report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
There has been no change in the Company’s internal controls over financial reporting during the fiscal quarter ended December 31, 2004, that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.
22
PART II
OTHER INFORMATION
| Item 1. | Legal Proceedings |
See Note 8, Commitments and Contingencies to the Consolidated Financial Statements.
| Item 2. | Changes in Securities and Use of Proceeds |
Not Applicable
| Item 3. | Defaults upon Senior Securities |
See Note 3, Convertible Debt
| Item 4. | Submission of Matters to a Vote of Security Holders |
Not Applicable
| Item 5. | Other Information |
Not Applicable
| Item 6. | Exhibits and Reports on Form 8-K |
| 31.1 | Written Statement of the Chief Executive Officer Pursuant to 18 U.S.C. §1350 Sec. 302 |
| 31.2 | Written Statement of the Chief Financial Officer Pursuant to 18 U.S.C. §1350 Sec. 302 |
| 32.1 | Written Statement of the Chief Executive Officer Pursuant to 18 U.S.C. §1350 Sec. 906 |
| 32.2 | Written Statement of the Chief Financial Officer Pursuant to 18 U.S.C. §1350 Sec. 906 |
23
United Energy Corp.
FORM 10-QSB
December 31, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: February 14, 2005 | | | UNITED ENERGY CORP. |
| | | | By: | /s/ Brian King
|
| | | | |
|
| | | | | Brian King, Chief Executive Officer (as principal executive officer) |
| | |
| | | | By: | /s/ James McKeever
|
| | | | |
|
| | | | | James McKeever, Interim Chief Financial Officer (as principal financial and accounting officer) |
24